Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration by Mattes, Dietmar et al.
Analysis of three pigment epithelium-derived factor gene
polymorphisms in patients with exudative age-related macular
degeneration
Dietmar Mattes,1 Anton Haas,1 Wilfried Renner,2 Iris Steinbrugger,1 Yosuf El-Shabrawi,1 Andreas Wedrich,1
Christoph Werner,1 Otto Schmut,1 Martin Weger1
1Department of Ophthalmology, Medical University of Graz, Austria; 2Clinical Institute of Medical and Chemical Laboratory
Diagnostics, Medical University of Graz, Austria
Purpose: Exudative age-related macular degeneration (exudative AMD) is a common vision-threatening disease, with
both environmental and genetic factors contributing to its development. Recently, homozygosity for the 72Met variant of
the pigment epithelium-derived factor (PEDF) Met72Thr gene polymorphism (rs1136287) was identified as a novel risk
factor for exudative AMD in Chinese patients from Taiwan. The role of this polymorphism, however, has not yet been
determined  in  a  white  European  population.  In  addition,  two  other  PEDF  gene  polymorphisms,  −5736T>C
(rs12150053) and −5304C>T (rs12948385), have been associated with increased risk of diabetic retinopathy, but have
not yet been studied among patients with exudative AMD. The purpose of the present study was thus to investigate a
hypothesized association between these PEDF polymorphisms and the presence of exudative AMD in a white European
population.
Methods:  The  present  case-control  study  comprised  269  patients  with  exudative  AMD  and  155  control  subjects.
Genotypes of the PEDF polymorphisms were determined by 5′-exonuclease assays (TaqMan).
Results: PEDF genotype and allele frequencies were not significantly different between AMD patients and control
subjects. The two promoter polymorphisms, −5736T>C (rs12150053) and −5304C>T (rs12948385), were in complete
association. Presence of the homozygous PEDF 72 Met/Met genotype was associated with a nonsignificant odds ratio of
1.00 (95% confidence interval: 0.67–1.49, p=0.99). Similarly, presence of the homozygous PEDF −5736 TT genotype or
−5304 CC genotype was associated with a nonsignificant odds ratio of 0.99 (95% confidence interval: 0.56 - 1.75, p=0.97).
Both promoter polymorphisms were in linkage disequilibrium with the Met72Thr (rs1136287) polymorphism (D'=0.83)
and formed three common and one rare haplotype. Haplotype frequencies were similar between AMD patients and control
subjects (p>0.05).
Conclusions: Our data suggest that none of the investigated PEDF polymorphisms is likely a major risk factor for
exudative AMD in a white European population.
Exudative age-related macular degeneration (exudative
AMD) is a major cause of severe visual impairment in patients
older than 50 years [1–3]. An impaired balance between pro-
and antiangiogenic factors has previously been implicated in
the development of choroidal neovascularization in AMD [4–
6].
Pigment  epithelium-derived  factor  (PEDF),  a  50  kDa
glycoprotein  belonging  to  the  serine  proteinase  inhibitor
family [7–10], is a potent antiangiogenic factor [11,12] and
exerts neurotrophic and neuroprotective effects [8,13]. It is
synthesized by several different cell types including retinal
pigment  epithelium  (RPE)  cells  and  photoreceptors  [14].
Several  lines  of  evidence  indicate  a  role  of  PEDF  in  the
pathogenesis of exudative AMD. First, immunohistochemical
studies have revealed significantly reduced immunoreactivity
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for PEDF in both RPE cells and in Bruch’s membrane of AMD
eyes  compared  with  healthy  control  eyes  [6,15].  Second,
vitreous PEDF concentrations were found to be significantly
decreased  in  eyes  with  exudative  AMD  [16].  Additional
evidence comes from an animal laser injury model showing
an  inverse  correlation  between  PEDF  expression  and
formation of choroidal neovascularizations [17,18]. Finally,
the administration of recombinant natural PEDF or adenoviral
vector-delivered PEDF has been found either to inhibit the
development of choroidal neovascularizations or to reduce its
extent [19–21].
In 2005, Yamagishi et al. [22] proposed the hypothesis
that a PEDF gene polymorphism, which is characterized by a
methionine to threonine substitution at amino acid position 72
of  PEDF  (PEDF  Met72Thr  [PEDF  311T>C],  rs1136287)
[23], might be a genetic marker for AMD. Indeed, Lin et al.
[24] only recently identified this polymorphism as a novel risk
factor for exudative AMD in a Taiwan Chinese population.
So far, this finding has not yet been replicated in a white
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343European population. This, however, is essential to draw firm
conclusions  on  the  potential  contribution  of  gene
polymorphisms  to  exudative  AMD  risk  in  populations  of
different  ethic  origin.  Two  other  PEDF  polymorphisms,
−5736T>C (rs12150053) and −5304C>T (rs12948385), have
only recently been associated with diabetic retinopathy, but
have not yet been studied in AMD patients [25]. The purpose
of the present study was thus to investigate a hypothesized
association  between  the  aforementioned  PEDF
polymorphisms and exudative AMD in a white European
population.
METHODS
The study comprised 269 patients with exudative AMD and
155 control participants who were of European origin and
living in the same geographical area in the southern part of
Austria. All participants were seen at the local Department of
Ophthalmology, Medical University of Graz, and gave written
informed consent before enrollment. The study was conducted
according  to  the  Austrian  Gene  Technology  Act  and  the
guidelines of the local Ethics Committee.
Exudative  AMD  was  diagnosed  by  ophthalmoscopic
fundus  examination,  followed  by  fluorescein/indocyanine
angiography  revealing  choroidal  neovascularizations.
Exclusion  criteria  comprised  the  presence  of  choroidal
polypoidal  vasculopathy  or  secondary  choroidal
neovascularizations due to pathologic myopia (>6 diopters,
spherical  equivalent),  inflammatory  or  infectious
chrorioretinal diseases, trauma, angioid streaks or hereditary
diseases.
Each  control  participant  underwent  a  detailed  eye
examination  that  included  fundus  examination.  Exclusion
criteria  were  defined  as  any  evidence  of  age-related
maculopathy (drusen as well as pigmentary changes), macular
hemorrhages  of  any  cause,  or  media  opacities  leading  to
impaired visualization of the macula.
Genotype determination: Venous blood drawn from the
antecubital vein was collected in ethylene diamine tetraacetic
acid tubes. Genomic DNA was isolated from whole blood
using a commercial kit (QIA_AMP DNA blood mini kit;
Qiagen,  Vienna,  Austria)  and  stored  at  −20  °C.  PEDF
genotype  were  determined  by  5′-exonuclease  assays
(TaqMan). Primers and probes are summarized in Table 1.
Fluorescence was measured in a lambda Fluoro 320 Plus plate
reader  (MWG  Biotech  AG,  Penzberg,  Germany)  using
excitation/emission filters of 485/530 nm for probes labeled
with fluorescent dye FAM and 530/572 nm for probes labeled
with fluorescent dye VIC. The data were exported into Excel
format,  depicted  and  analyzed  as  a  scatter  plot.  The
technicians responsible for genotyping were blinded for case/
control status.
Statistics: SPSS for Windows (release 14.0; SPSS, Inc.)
was used for statistical analyses. Continuous variables were
analyzed by t-test and presented as mean±standard deviation
(SD). Categorical variables are presented as percentages and
were compared as chi-square test. Odds ratios (OR) and 95%
confidence  intervals  (CI)  were  determined  by  logistic
regression analysis. The criterion for statistical significance
was p<0.05.
RESULTS
Clinical  characteristics  of  AMD  patients  and  control
participants are presented in Table 2. Table 3 shows PEDF
genotype distribution in AMD patients and controls. In both
groups, the observed genotype distributions were in line with
those predicted by the Hardy–Weinberg equilibrium. PEDF
genotype  and  allele  frequencies  were  not  significantly
different between AMD patients and controls (Table 3). The
TABLE 1. SEQUENCES OF PRIMERS AND PROBES USED FOR THE DETERMINATION OF THE PEDF GENOTYPES.
PEDF polymorphism Primers (5′-3′) and probes












PEDF genotypes were determined by 5′-exonuclease assays (TaqMan) using probes labeled with fluorescent dyes VIC or FAM.
Abbreviations used in the table: F represents forward primer, R represents reverse primer, WT represents wild-type.
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344two promoter polymorphisms, −5736T>C (rs12150053) and
−5304C>T (rs12948385), were in complete association.
Presence of the homozygous PEDF 72 Met/Met genotype
was associated with a nonsignificant OR of 1.00 (95% CI:
0.67–1.49, p=0.99). Similarly, presence of the homozygous
PEDF−5736  TT  genotype  or  −5304  CC  genotype  was
associated with a nonsignificant OR of 0.99 (95% CI: 0.56–
1.75, p=0.97). The observed OR was not substantially altered
after adjustment of smoking habits (data not shown).
Both  promoter  polymorphisms  were  in  linkage
disequilibrium  with  the  Met72Thr  (rs1136287)
polymorphism (D'=0.83). In total, three common haplotypes
and  one  rare  haplotype  were  formed  by  the  PEDF
polymorphisms investigated in the present study. Haplotype
frequencies were similar between AMD patients and controls
(Table 4).
DISCUSSION
Exudative AMD has previously been shown to have a strong
genetic component [26–39]. Only recently, a significantly
increased prevalence of the PEDF 72 Met/Met genotype was
reported in a Taiwan Chinese population, yielding an OR of
3.9 for exudative AMD [24]. This, however, has not yet been
confirmed in other populations of different ethnic origin.
To the best of our knowledge, the present study is the first
to investigate the potential role of this polymorphism in a
white European population. In contrast to the findings of Lin
et al. [24], homozygosity for the PEDF 72Met  allele was not
found to be significantly more prevalent in AMD patients
compared  with  controls.  Importantly,  our  study  had  a
statistical power of 0.8 to detect or exclude an OR greater than
or equal to 1.8. Thus, our data strongly suggest that the PEDF
Met72Thr polymorphism itself is unlikely a major risk factor
for exudative AMD in a white European population.
Interestingly,  the  PEDF  72Met   allele  frequency  was
0.652 in our control group of white European subjects, which
is substantially higher than the PEDF 72Met  allele frequency
of 0.311 found in a Taiwan Chinese population [24]. This
finding  indicates  that  genotype  distributions  of  this
TABLE 2. CLINICAL CHARACTERISTICS OF EXUDATIVE AMD PATIENTS AND CONTROLS.
Clinical characteristics Exudative AMD patients (n=269) Controls (n=155)
Females 178 (66.2) 86 (55.5)
Mean age±SD (years) 78.4±7.0 77.4±6.5
Range (years) 55.8–94.1 53.2–91.1
Body mass index * 26.3±3.9 26.7±4.0
Arterial hypertension 161 (59.9) 111 (71.6)
Hypercholesterolemia 193 (71.7) 101 (65.2)
Diabetes mellitus 26 (9.7) 22 (14.2)
Myocardial infarction 19 (7.1) 13 (8.4)
History of smoking 75 (27.9) 34 (21.9)
Numbers are given as n (%). Abbreviations: age-related macular degeneration (AMD); standard deviation (SD). The asterisk
indicates that the data on body mass index were available from 205 AMD patients and 151 control subjects.
TABLE 3. PEDF GENOTYPES IN EXUDATIVE AMD PATIENTS AND CONTROLS.
Polymorphism Genotype Exudative AMD patients (n=269) Controls (n=155) p
Met72Thr (rs1136287) Met/Met 111 (41.3%) 64 (41.3%) 0.81
Met/Thr 123 (45.7%) 74 (47.7%)
Thr/Thr 35 (13.0%) 17 (11.0%)
MAF 0.359 0.348 0.76
−5736T>C(rs12150053) TT 108 (40.1%) 67 (43.2%) 0.71
TC 117 (43.5%) 61 (39.4%)
CC 44 (16.4%) 27 (17.4%)
MAF 0.381 0.371 0.77
−5304C>T (rs12948385) CC 108 (40.1%) 67 (43.2%) 0.71
CT 117 (43.5%) 61 (39.4%)
TT 44 (16.4%) 27 (17.4%)
MAF 0.381 0.371 0.77
Data indicate the number of eyes with and without exudative age-related macular degeneration (AMD), respectively. Numbers
are given as n (%). Neither PEDF genotypes nor minor allele frequencies (MAF) were significantly associated with exudative
AMD.
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345polymorphism vary widely between different populations and
thus  underlines  the  importance  of  performing  genetic
association studies in various ethnicities.
As PEDF expression in RPE cells is also influenced by
other factors such as oxidative stress [40], our finding that the
PEDF  Met72Thr  polymorphism  is  not  associated  with
exudative  AMD  risk  in  an  European population does not
argue   against   a   role   of   PEDF     in   AMD.   Beside the
Met72Thr polymorphisms, other PEDF   gene variations may
be      associated      with      exudative     AMD.     Recently,  two
polymorphisms  in  the  PEDF  promoter,  −5736T>C
(rs12150053)  and  −5304C>T  (rs12948385),  but  not  the
Met72Thr polymorphism, were found to be associated with
diabetic retinopathy [25,41]. The present study is also the first
to  investigate  the  potential  association  of  these
polymorphisms with exudative AMD. A major finding of our
study  was  that  the  two  polymorphisms  did  not  confer  a
significantly increased risk for exudative AMD in a white
European population.
Currently, the functionality of the PEDF polymorphisms
investigated  in  the  present  study  is  unclear.  A  variety  of
putative binding sites for transcription factors and two Alu
repetitive  sequences  have  been  described  in  the  PEDF
promoter  [9],  but  the  two  promoter  polymorphisms
(−5736T>C [rs12150053] and −5304C>T [rs12948385]) we
investigated do not affect any of these putative binding sites.
The Met72Thr polymorphism lies at the end of a helix domain
of  the  PEDF  protein  and  results  in  the  exchange  of  a
hydrophobic amino acid (methionine) by a polar amino acid
(threonine) [23]. Nevertheless, the functional consequences
of  this  exchange  are  currently  unknown.  Further  studies
investigating the influence of these polymorphisms on the
expression and function of the PEDF protein will be necessary
to clarify their functionality.
Previous studies have clearly demonstrated that PEDF
itself  is  able  to  inhibit  the  development  of  choroidal
neovascularizations [19–21]. Considering the antiangiogenic
and anti-vasopermeability effects of PEDF [11,12], it remains
to be determined whether gene polymorphisms affecting the
expression of PEDF in the chorioretinal tissue may modulate
the efficacy as well as frequency of anti-vascular endothelial
growth factor treatment. Thus, further studies focusing on the
identification of functional PEDF polymorphisms and their
potential association with treatment outcome might be of great
interest.
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